Myeloproliferative Neoplasms

Dr Abdulraheem Yacoub explains allogeneic hematopoietic cell transplantation in myelofibrosis, the only known curative treatment modality.

The panel reviews the types of myelofibrosis, discusses how to risk stratify and explains the role of biomarker testing in patients with MF.

Rami Komrokji, MD, discusses the clinical implications of the phase 3 COMMANDS trial in patients with very low–, low-, or intermediate-risk myelodysplastic syndromes who have not received prior treatment with an erythropoiesis-stimulating agents.

Panelists review the presented patient profile and shares how they would have approached treatment.

Dr Brunner presents the patient profile of a 75-year-old man with transfusion-dependent, lower-risk MDS and symptomatic anemia.

Anna B. Halpern, MD, discusses strides in the treatment of myelofibrosis with anemia, the shifting role of ruxolitinib in this disease, and the importance of providing patients with access to clinical trials.

Dr Jamile Shammo reviews recent data on the treatment of patients with polycythemia vera with ropeginterferon.

Andrew Brunner, MD, reviews the available second-line treatment options for lower-risk MDS with symptomatic anemia.

Abdulraheem Yacoub, MD, reviews data from the RESPONSE and RESPONSE-2 trials on the use of ruxolitinib for the treatment of polycythemia vera.

Dr Madanat defines erythropoiesis-stimulating agent (ESA) treatment failure in lower-risk MDS with symptomatic anemia and describes his approach to monitoring patients.

John O. Mascarenhas, MD, discusses the design and rationale of the KRT-232-109 trial, key findings from the trial, and potential future directions of the study.

The FDA has lifted a partial clinical hold on the phase 1/2 TakeAim Leukemia trial evaluating emavusertib monotherapy and in combination with azacitidine and venetoclax in patients with relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndrome.

The panel shares at what point they decide to start treatment for patients with lower-risk MDS and symptomatic anemia.

Jamile Shammo, MD, explains how she decides on the most appropriate treatment option for a patient with polycythemia vera.

Yazan Madanat, MD, details the available options for first-line treatment of patients with lower-risk MDS and symptomatic anemia.

Drs Rampal and Yacoub details the currently available treatment options and reviews the rationale for use in patients with PV.

Harry Gill, MD, discusses the rationale for exploring ropeginterferon alfa-2b as a potential treatment option for patients early myelofibrosis and expands on the efficacy and safety data observed in the phase 2 study.

Dr Jamile Shammo describes how risk is assessed for patients with polycythemia vera.

Rami Komrokji, MD, discusses key findings from an expanded analysis of the classification of patients with myelodysplastic syndromes.

Experts provide an overview of myeloproliferative neoplasms, including the subtypes, process of diagnosis as well as reviewing the role of biomarkers.

Amer Zeidan, MBBS, MHS, explains risk stratification in MDS, how the process has evolved over time, and the guidelines he typically follows.

Hetty Carraway, MD, reviews how MDS is diagnosed and the common symptoms that patients who have MDS may present with.

John Mascarenhas, MD, discusses initial clinical activity observed with the addition of the first-in-class MDM2 inhibitor navtemadlin to ruxolitinib in primary or secondary myelofibrosis.

John M. Burke, MD, expands on the use of novel BTK inhibitor regimens in mantle cell lymphoma, treatment sequencing challenges and other unmet needs in diffuse-large B-cell lymphoma, the evolution of management strategies for myeloproliferative neoplasms, and the potential influence of new and emerging therapeutics in chronic lymphocytic leukemia.

Rami Komrokji, MD, discusses ongoing clinical trials in patients with higher- and lower-risk myelodysplastic syndromes.